Zhihang Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhihang Shen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Chenglong Li
University of Florida
5 shared publications - Gustavo Seabra
University of Florida
3 shared publications - Allison L. Bayer
Division of Endocrinology, Diabetes, and Metabolism Department of Medicine University of Miami Miller School of Medicine Miami FL
1 shared publication Amandeep Singh
Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
1 shared publicationArun K. Sharma
Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
1 shared publicationBenjamin Lewis
Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States
1 shared publication
Latest Publications
- Open Access
- 23 March 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (3) , 482
Functional Evaluation of Computationally Designed IL-10 in IL-10 KO Mice
Studies have shown that IL-10 has therapeutic potential for inflammatory diseases. However, it is challenging to use IL-10 as a therapeutic drug because it also possesses pro-inflammatory functions. To reduce these pro-inflammatory effects of IL-10, we have designed three IL-10 mutants using structure-based computational design technology. We demonstrated that these mutants exhibited significantly lower activity in IL-10-responsive cell lines than wild-type IL-10. Using recombinant adeno-associated virus (rAAV8) vectors expressing wild-type or mutant IL-10 molecules, we performed gene therapy experiments in IL-10 KO mice. The results showed that our vectors mediated high levels of transgene expression. Importantly, IL-10 gene therapy increased body weight gain, reduced colon injury, and prevented the development of inflammatory bowel disease (IBD). Moreover, IL-10 mutant gene therapy elicited significantly lower stimulation of CD8 T and NK cells compared with the wild-type IL-10 group. In summary, our IL-10 mutants provide a protective effect comparable to wild-type IL-10 in the IL-10 KO mouse model, suggesting that they may potentially have reduced pro-inflammatory function. While rigorous investigations of safety and efficacy in different disease models will be required, these results indicate the therapeutic potential of IL-10 mutant gene therapy for inflammatory diseases such as IBD.
- 23 March 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (3) , 482
Open AccessFunctional Evaluation of Computationally Designed IL-10 in IL-10 KO Mice
Studies have shown that IL-10 has therapeutic potential for inflammatory diseases. However, it is challenging to use IL-10 as a therapeutic drug because it also possesses pro-inflammatory functions. To reduce these pro-inflammatory effects of IL-10, we have designed three IL-10 mutants using structure-based computational design technology. We demonstrated that these mutants exhibited significantly lower activity in IL-10-responsive cell lines than wild-type IL-10. Using recombinant adeno-associated virus (rAAV8) vectors expressing wild-type or mutant IL-10 molecules, we performed gene therapy experiments in IL-10 KO mice. The results showed that our vectors mediated high levels of transgene expression. Importantly, IL-10 gene therapy increased body weight gain, reduced colon injury, and prevented the development of inflammatory bowel disease (IBD). Moreover, IL-10 mutant gene therapy elicited significantly lower stimulation of CD8 T and NK cells compared with the wild-type IL-10 group. In summary, our IL-10 mutants provide a protective effect comparable to wild-type IL-10 in the IL-10 KO mouse model, suggesting that they may potentially have reduced pro-inflammatory function. While rigorous investigations of safety and efficacy in different disease models will be required, these results indicate the therapeutic potential of IL-10 mutant gene therapy for inflammatory diseases such as IBD.
- Open Access
Targeting PRMT5: Current Inhibitors and Emerging Strategies for Therapeutic Intervention
Epigenetic dysregulation is a hallmark of tumorigenesis, with arginine methylation—a post-translational modification—emerging as a key regulatory mechanism in cancer biology. This modification, catalyzed by protein arginine methyltransferases (PRMTs), influences critical cellular processes, including proliferation, differentiation, transcription, RNA splicing, DNA repair, and immune signaling. Among the PRMT family, PRMT5 has garnered significant attention due to its elevated expression across various solid tumors and hematological malignancies, and its strong association with poor clinical outcomes. Notably, PRMT5 exhibits a unique vulnerability in methyl-thio-adenosine phosphorylase (MTAP)-deficient cancers, making it an attractive therapeutic target. Recent advances have led to the development of several PRMT5 inhibitors with diverse binding modes, some of which have progressed into clinical trials for advanced cancers. This review provides a structural and mechanistic overview of PRMT5, summarizes current inhibition strategies, and discusses the challenges and future directions in targeting PRMT5 for cancer therapy.
Open AccessTargeting PRMT5: Current Inhibitors and Emerging Strategies for Therapeutic Intervention
Epigenetic dysregulation is a hallmark of tumorigenesis, with arginine methylation—a post-translational modification—emerging as a key regulatory mechanism in cancer biology. This modification, catalyzed by protein arginine methyltransferases (PRMTs), influences critical cellular processes, including proliferation, differentiation, transcription, RNA splicing, DNA repair, and immune signaling. Among the PRMT family, PRMT5 has garnered significant attention due to its elevated expression across various solid tumors and hematological malignancies, and its strong association with poor clinical outcomes. Notably, PRMT5 exhibits a unique vulnerability in methyl-thio-adenosine phosphorylase (MTAP)-deficient cancers, making it an attractive therapeutic target. Recent advances have led to the development of several PRMT5 inhibitors with diverse binding modes, some of which have progressed into clinical trials for advanced cancers. This review provides a structural and mechanistic overview of PRMT5, summarizes current inhibition strategies, and discusses the challenges and future directions in targeting PRMT5 for cancer therapy.
- 29 May 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (6) , 1333-1346
Discovery and Mechanism of 16–19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells
Protein arginine methyltransferase 5 (PRMT5), which uniquely binds to 5'-methylthioadenosine (MTA) among the PRMT family, is emerging as an attractive epigenetic target for 5'-methylthioadenosine phosphorylase (MTAP)-deleted cancer treatments. Here, we report the discovery of a novel inhibitor 16-19F, which is a potent binder to the PRMT5•MTA, PRMT5•SAH, and PRMT5•SAM complexes and selectively inhibited MTAP-deleted cancer cell growth. Based on transcriptome analysis, we found that kinetochore metaphase signaling and cell cycle control of the chromosomal replication pathway were downregulated after 16-19F treatment in the MDA-MB-231 TNBC cell line. Additionally, we identified a new PRMT5 substrate, MCM7, an important component of DNA helicase, and figured out the potential methylation site Arg219 by site-directed mutagenesis and computational analysis. Moreover, we showed that 16-19F treatment regulated MCM7 localization, which is involved through liquid-liquid phase separation mechanisms, including the formation of stress granules. Together, we discovered a potential novel drug candidate and revealed an unknown mechanism in which PRMT5 methylation altered MCM7 localization by modulating stress granule formation.
- 29 May 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (6) , 1333-1346
Discovery and Mechanism of 16–19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells
Protein arginine methyltransferase 5 (PRMT5), which uniquely binds to 5'-methylthioadenosine (MTA) among the PRMT family, is emerging as an attractive epigenetic target for 5'-methylthioadenosine phosphorylase (MTAP)-deleted cancer treatments. Here, we report the discovery of a novel inhibitor 16-19F, which is a potent binder to the PRMT5•MTA, PRMT5•SAH, and PRMT5•SAM complexes and selectively inhibited MTAP-deleted cancer cell growth. Based on transcriptome analysis, we found that kinetochore metaphase signaling and cell cycle control of the chromosomal replication pathway were downregulated after 16-19F treatment in the MDA-MB-231 TNBC cell line. Additionally, we identified a new PRMT5 substrate, MCM7, an important component of DNA helicase, and figured out the potential methylation site Arg219 by site-directed mutagenesis and computational analysis. Moreover, we showed that 16-19F treatment regulated MCM7 localization, which is involved through liquid-liquid phase separation mechanisms, including the formation of stress granules. Together, we discovered a potential novel drug candidate and revealed an unknown mechanism in which PRMT5 methylation altered MCM7 localization by modulating stress granule formation.
- 24 April 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 875-879
Virtual High-Throughput Screening of Ligands for Disrupting PRMT5/pICLn Interaction in Prostate Cancer Cells
Prostate cancer (PC) is the most commonly diagnosed cancer in men worldwide. While androgen deprivation therapy (ADT) is initially effective, many patients develop resistance, progressing to castration-resistant prostate cancer (CRPC). Recent studies have identified the interaction between PRMT5 (protein arginine methyltransferase 5) and pICLn as a promising therapeutic target, as it promotes the transcription of double-strand break (DSB) repair genes that contribute to therapy resistance. To target this pathway, a screening campaign identified J021-0199 as a potential hit compound that disrupts the PRMT5/pICLn interaction. Biochemical assays demonstrated that J021-0199 binds to the N-terminal TIM barrel domain of PRMT5. In CRPC cell lines (LNCaP and 22Rv1), J021-0199 selectively inhibited cancer cell growth. qPCR analysis further revealed downregulation of DNA damage response (DDR) genes involved in homologous recombination, nonhomologous end joining, and G2 arrest. These results support J021-0199 as a promising lead compound for overcoming resistance in CRPC.
- 24 April 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (5) , 875-879
Virtual High-Throughput Screening of Ligands for Disrupting PRMT5/pICLn Interaction in Prostate Cancer Cells
Prostate cancer (PC) is the most commonly diagnosed cancer in men worldwide. While androgen deprivation therapy (ADT) is initially effective, many patients develop resistance, progressing to castration-resistant prostate cancer (CRPC). Recent studies have identified the interaction between PRMT5 (protein arginine methyltransferase 5) and pICLn as a promising therapeutic target, as it promotes the transcription of double-strand break (DSB) repair genes that contribute to therapy resistance. To target this pathway, a screening campaign identified J021-0199 as a potential hit compound that disrupts the PRMT5/pICLn interaction. Biochemical assays demonstrated that J021-0199 binds to the N-terminal TIM barrel domain of PRMT5. In CRPC cell lines (LNCaP and 22Rv1), J021-0199 selectively inhibited cancer cell growth. qPCR analysis further revealed downregulation of DNA damage response (DDR) genes involved in homologous recombination, nonhomologous end joining, and G2 arrest. These results support J021-0199 as a promising lead compound for overcoming resistance in CRPC.
- Open Access
- 2 January 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (1) , 1156-1163
Discovery of PRMT5 N-Terminal TIM Barrel Ligands from Machine-Learning-Based Virtual Screening
Protein arginine methyltransferase 5 (PRMT5), which symmetrically dimethylates cytosolic and nuclear proteins, has been demonstrated as an important cancer therapeutic target. In recent years, many advanced achievements in PRMT5 inhibitor development have been made. Most PRMT5 inhibitors in the clinical trial focus on targeting the C-terminal catalytic domain, whereas developing small molecules to interrupt the PRMT5/pICLn (methylosome subunit) protein-protein interface is also of great importance for inhibiting PRMT5. Here, we describe a machine-learning-based virtual screening method and use this novel pipeline to screen small-molecule inhibitors of the PRMT5/pICLn interaction. 18 compounds were manually selected for experimental testing. One compound, Z319334062, showed surface plasmon resonance-binding affinity to the target (K D = 21.5 μM) and dose-dependently inhibited symmetric dimethylation levels in patient-derived glioblastoma cell lines.
- 2 January 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (1) , 1156-1163
Open AccessDiscovery of PRMT5 N-Terminal TIM Barrel Ligands from Machine-Learning-Based Virtual Screening
Protein arginine methyltransferase 5 (PRMT5), which symmetrically dimethylates cytosolic and nuclear proteins, has been demonstrated as an important cancer therapeutic target. In recent years, many advanced achievements in PRMT5 inhibitor development have been made. Most PRMT5 inhibitors in the clinical trial focus on targeting the C-terminal catalytic domain, whereas developing small molecules to interrupt the PRMT5/pICLn (methylosome subunit) protein-protein interface is also of great importance for inhibiting PRMT5. Here, we describe a machine-learning-based virtual screening method and use this novel pipeline to screen small-molecule inhibitors of the PRMT5/pICLn interaction. 18 compounds were manually selected for experimental testing. One compound, Z319334062, showed surface plasmon resonance-binding affinity to the target (K D = 21.5 μM) and dose-dependently inhibited symmetric dimethylation levels in patient-derived glioblastoma cell lines.
- 30 January 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (3) , 937-962
Molecular editing of NSC-666719 enabling discovery of benzodithiazinedioxide-guanidines as anticancer agents
In this study, a unique strategy of scaffold-hopping-based molecular editing of a bioactive agent NSC-666719 was investigated, which led to the development of new benzodithiazinedioxide-guanidine based anticancer agents with Polβ inhibition.
- 30 January 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (3) , 937-962
Molecular editing of NSC-666719 enabling discovery of benzodithiazinedioxide-guanidines as anticancer agents
In this study, a unique strategy of scaffold-hopping-based molecular editing of a bioactive agent NSC-666719 was investigated, which led to the development of new benzodithiazinedioxide-guanidine based anticancer agents with Polβ inhibition.